Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXWFP2)

• Drug Name: A337 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMXWFP2

Molecule-Related Drug Atlas

Drug(s) Targeting Cytotoxic T-lymphocyte protein 4 (CTLA-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ipilimumab	DMJTIYK	Melanoma	2C30	Approved	[2]
Tremelimumab	DMOQ9H1	Hepatocellular carcinoma	2C12.02	Approved	[3]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[4]
AK04	DMU7K86	Actinic keratosis	EK90.0	Phase 3	[5]
AK104	DMXJ8Z4	Cervical cancer	2C77.0	Phase 2	[6]
Lorigerlimab	DM2E8Z5	Prostate cancer	2C82.0	Phase 2	[7]
Vudalimab	DMSEEI0	Prostate cancer	2C82.0	Phase 2	[8]
AGEN1884	DMAP5B4	Cervical cancer	2C77.0	Phase 1/2	[9]
BMS-986288	DMM10J4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
MK-1308	DM25QKC	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[11]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[12]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[13]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[14]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[15]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[16]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[17]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[4]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[18]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[19]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Not Available	[1]
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Klus Pharma
• [2] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
• [4] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [5] A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
• [6] Clinical pipeline report, company report or official report of Akeso Biopharma.
• [7] Clinical pipeline report, company report or official report of MacroGenics
• [8] Clinical pipeline report, company report or official report of Xencor
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of CytomX Therapeutics.
• [11] Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
• [12] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [14] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [15] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [17] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [18] National Cancer Institute Drug Dictionary (drug id 740856).
• [19] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [20] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.